Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-12	7.620 $	+19.81%	6,653
26-02-11	6.360 $	-11.67%	1,001
26-02-10	7.200 $	+13.92%	3,316
26-02-06	6.320 $	-12.59%	815

Delayed Quote Canadian Securities Exchange

More quotes

Income Statement and Estimates

More financial data

Market Closed - Canadian Securities Exchange Other stock markets 03:59:59 2026-02-12 pm EST			5-day change	1st Jan Change
7.620 ^CAD	0.00%		+20.57%	+13.73%

Feb. 09	InnoCan Pharma Says Latest LPT-CBD Trial Involving Dogs Published in Peer-Reviewed Journal	MT
Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT

Capitalization	22.03M 18.56M 16.93M 16.16M 30M 1.99B 31.17M 197M 78.16M 963M 82.6M 80.91M 3.37B	P/E ratio 2023	-12.8x	P/E ratio 2024	-22.3x
Enterprise value	17.03M 14.35M 13.09M 12.49M 23.19M 1.54B 24.1M 152M 60.43M 745M 63.86M 62.55M 2.6B	EV / Sales 2023	4,324,363x	EV / Sales 2024	1,252,876x
Free-Float	77.49%	Yield 2023 *	-	Yield 2024	-

Feb. 09	InnoCan Pharma Says Latest LPT-CBD Trial Involving Dogs Published in Peer-Reviewed Journal	MT
Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT
Jan. 02	InnoCan Pharma to List on NYSE American Next Week	MT
Jan. 02	Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering	MT
Dec. 10	InnoCan Announces Public Filing of Amended Registration Statement For Proposed U.S. Offering	MT
Nov. 27	Innocan Pharma Nine-month Operating Loss Stable, Revenue Fall 10%	MT
Nov. 26	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 24	Innocan Pharma Corporation Announces Promising Translational Evidence from A Pain Relief Study of Repeated Lpt-Cbd Administration in Goats	CI
25-10-15	Innocan Pharma Corporation Announces Its Patent for Lpt-Cbd Is Allowed in Japan	CI
25-09-18	Innocan Pharma Corporation Partners with Freedom Farm to Bring Remedy and Hope with its LPT-CBD Injection	CI
25-08-29	InnoCan Pharma Plans One-for-65 Share Consolidation Ahead of Nasdaq Listing	MT
25-08-29	Innocan Pharma announces details of proposed share consolidation	RE
25-08-27	InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Jan. 27	Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering	AQ
Dec. 10	Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering	AQ
Nov. 27	Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M	AQ
Nov. 26	InnoCan Pharma : Financial Statements as of September 30, 2025	PU
Nov. 26	InnoCan Pharma : MD&A Report For Nine Months Period Ended September 30, 2025	PU

InnoCan Pharma Corporation Stock

Equities

INNO

CA45783P5085

Pharmaceuticals

Valuation: InnoCan Pharma Corporation

Chart: InnoCan Pharma Corporation

Latest news: InnoCan Pharma Corporation

Press Releases: InnoCan Pharma Corporation

News in other languages: InnoCan Pharma Corporation

Quotes and Performance

Course Extremes

Managers and Directors: InnoCan Pharma Corporation

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

21-11-10	InnoCan Pharma Corporation: Innocan -2-
21-11-10	InnoCan Pharma Corporation: Innocan Pharma berichtet über weitere Erfolge bei der Profilcharakterisierung von Mikro-RNA in seinem Projekt für eine Verabreichungsplattform für mit Cannabinoiden beladenen Exosomen (CLX)
21-11-05	InnoCan Pharma Corporation: Innocan -2-
21-11-05	InnoCan Pharma Corporation: Innocan Pharma meldet 100%ige Ausübung der im Rahmen der Privatplatzierung im Dezember 2020 begebenen Warrants
21-10-28	InnoCan Pharma Corporation: Innocan Pharma-CEO Iris Bincovich hält am 29. Oktober 2021 einen Vortrag auf einer Investorenveranstaltung in München

1 week	+20.57%
Current month	-19.54%
1 month	-5.93%
3 months	-53.82%
6 months	-46.71%
Current year	+13.73%

1 week	5.76	8.06
1 month	5.76	11.44
Current year	5.76	11.44
1 year	5.76	21
3 years	5.76	33.8
5 years	5.76	107.25
10 years	3.25	107.25

Manager	Title	Age	Since
Nir Avram CTO	Chief Tech/Sci/R&D Officer	73	-
Iris Bincovich CEO	Chief Executive Officer	-	2018-05-30
Nelson Halpern DFI	Director of Finance/CFO	-	2019-02-19

Director	Title	Age	Since
Peter Bloch BRD	Director/Board Member	66	2020-01-21
Iris Bincovich CHM	Chairman	-	2025-06-30
Eyal Flom BRD	Director/Board Member	61	2019-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INNOCAN PHARMA CORPORATION	0.00%	+20.57%	-38.30%	-58.87%	25.17M
ELI LILLY AND COMPANY	+0.33%	-1.72%	+23.18%	+199.23%	929B
JOHNSON & JOHNSON	-0.45%	+1.44%	+55.91%	+50.24%	587B
ABBVIE INC.	+1.76%	+3.61%	+20.03%	+51.71%	409B
ROCHE HOLDING AG	+0.08%	+1.01%	+20.89%	+28.94%	374B
ASTRAZENECA PLC	+1.42%	+7.19%	+26.36%	+32.36%	320B
NOVARTIS AG	+1.08%	+4.32%	+27.98%	+55.61%	311B
MERCK & CO., INC.	+1.82%	-0.43%	+46.26%	+11.65%	301B
NOVO NORDISK A/S	+1.32%	+5.11%	-45.12%	-37.51%	219B
AMGEN INC.	+1.52%	-3.94%	+26.80%	+53.17%	199B
Average	+0.89%	+2.34%	+16.40%	+38.65%	364.88B
Weighted average by Cap.	+0.75%	+1.58%	+26.54%	+76.75%

	2023	2024
Net sales	13.66 11.51 10.5 10.02 18.6 1.24K 19.33 122.08 48.46 597.34 51.22 50.16 2.09K	29.44 24.8 22.62 21.6 40.09 2.67K 41.66 263.14 104.46 1.29K 110.39 108.13 4.5K
Net income	-4.7M -3.96M -3.61M -3.45M -6.4M -426M -6.65M -42.01M -16.68M -206M -17.63M -17.26M -718M	-1.83M -1.55M -1.41M -1.35M -2.5M -166M -2.6M -16.39M -6.51M -80.22M -6.88M -6.74M -280M
Net Debt	-3.85M -3.25M -2.96M -2.83M -5.25M -349M -5.45M -34.43M -13.67M -168M -14.45M -14.15M -589M	-5M -4.21M -3.84M -3.67M -6.81M -453M -7.07M -44.68M -17.74M -219M -18.74M -18.36M -764M